Siddhesh Rajendra Angle - 28 Sep 2026 Form 4 Insider Report for Bone Biologics Corp (BBLG)

Reporting relationship
Director
Issuer ticker
BBLG
Reported as of
28 Sep 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
30 Sep 2026, 17:12:42 UTC
Prior SEC filing
06 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Siddhesh Angle

Key filing fact

Siddhesh Rajendra Angle filed Form 4 for Bone Biologics Corp (BBLG) on 30 Sep 2026.

Key facts

  • This page summarizes Siddhesh Rajendra Angle's Form 4 filing for Bone Biologics Corp (BBLG).
  • 1 reported transaction and 8 derivative rows are listed below.
  • Accepted by SEC: 30 Sep 2026, 17:12.

Change

  • Previous filing in this sequence was filed on 06 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001889218 Primary reporting owner

Angle Siddhesh Rajendra

Relationship
Director
Address
C/O BONE BIOLOGICS CORP, 2 BURLINGTON WOODS DR. SUITE 100, BURLINGTON
Signature
/s/ Siddhesh Angle
Signature date
30 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBLG transaction Derivative

Non-Employee Stock Option

Award

Transaction value
Shares
+113,896
Change %
Price
$0.000000*
Shares after
113,896
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
113,896
Exercise price
$0.5000
Footnotes
F1
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,483
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,483
Exercise price
$5.28
Footnotes
F2
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,119
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,119
Exercise price
$10.38
Footnotes
F2
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,787
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,787
Exercise price
$30.72
Footnotes
F2
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
26
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
26
Exercise price
$2323.58
Footnotes
F2
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7
Exercise price
$5068.80
Footnotes
F2
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3
Exercise price
$7560.00
Footnotes
F2
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
13
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
13
Exercise price
$7560.00
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.

Footnote F2

This option is fully exercisable as of the date of this report.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .